{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-035390","form_type":"8-K","ticker":"WHWK","cik":"0001422142","company_name":"Whitehawk Therapeutics, Inc.","filed_at":"2024-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.004618+00:00","generated_at":"2026-05-31T11:41:15.709383+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Aadi Bioscience Q2 FYARRO sales $6.2M, net loss $14.6M; PRECISION1 interim analysis Q3","bullets":["FYARRO net product sales $6.2M for Q2 2024, up 15% quarter-over-quarter, flat YoY.","Net loss of $14.6M vs. $18.0M in Q2 2023; cash and investments $78.6M as of June 30, 2024.","Two-thirds interim analysis of fully enrolled PRECISION1 trial expected in Q3 2024.","Enrollment ongoing in Phase 2 trials for endometrial cancer and neuroendocrine tumors.","Cash runway expected to fund operations into Q4 2025 based on current plans."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-035390","json":"https://secwatch.observer/filing/0001628280-24-035390.json","markdown":"https://secwatch.observer/filing/0001628280-24-035390.md","text":"https://secwatch.observer/filing/0001628280-24-035390.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1422142/000162828024035390/0001628280-24-035390-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1422142/000162828024035390/aadi-20240807.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T11:41:15.709383+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}